PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. Sanofi holds a 20.6% stake in Regeneron, and has said it will shed around 12.8 million shares out of its current 23.2 million stake. PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. Sanofi announces closing of Regeneron stock sale. The longtime partnership between Regeneron and Sanofi continues to yield fruit. Regeneron has agreed to repurchase $5 billion of its stock from Sanofi conditional on completion of the proposed public offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. “Sanofi and Regeneron’s collaboration has been one of the most productive in the industry, creating significant value for both companies but more importantly, resulting in five important medicines for patients. This includes the previously announced overallotment option that has been fully exercised by underwriters. Regeneron also plans to buy back $5 billion worth of shares from Sanofi, which will leave the French pharma with 400,000 shares. PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. Sanofi announces closing of Regeneron stock sale. PARIS - May 25, 2020 – Sanofi today announced its intent to sell its equity investment in Regeneron (NASDAQ: REGN) through a registered public offering and related share repurchase by Regeneron. Click here for more information on cookies, Sanofi announces sale of 21.6 million shares held in Regeneron, Gross proceeds of $11.1 billion to Sanofi to further Company’s ability to execute innovation and growth strategy. Sanofi announces closing of Regeneron stock salePARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. Regeneron Pharmaceuticals, Inc. and its affiliates, Regeneron Ireland Unlimited Company and Regeneron UK Limited (together, "Regeneron", "we", "us" or "our") use this data to make the Sites more user-friendly and efficient. Following completion of the proposed public offering and share repurchase, Sanofi will discontinue accounting for its ownership in Regeneron’s common shares under the equity method. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. By continuing to browse this website, you agree to the use of such cookies. Before you invest, you should read the prospectus in that registration statement and other documents Regeneron has filed with the SEC, including the preliminary prospectus supplement dated May 26, 2020, for more complete information about Regeneron and this offering. Fitch has also affirmed Sanofi's … In addition, the companies are also conducting a second trial in countries outside of the U.S. The transaction has been approved by Sanofi and Regeneron’s Boards of Directors. The registered offering and share repurchase will have no impact on the ongoing collaboration between Sanofi and Regeneron. We believe the proceeds from this transaction will help further our ability to execute on our strategy to drive innovation and growth.”. Sanofi announces closing of Regeneron stock sale. Sanofi currently holds approximately 23.2 million shares of Regeneron’s common stock, representing approximately 20.6% ownership. The shares offered to the public are being offered pursuant to an existing effective shelf registration statement (including a base prospectus) that has been filed by Regeneron with the U.S. Securities and Exchange Commission (the "SEC"). By continuing to browse this website, you agree to the use of such cookies. This website uses cookies to track its audience and improve its content. Sanofi to Sell Its 20.6% Stake in Regeneron, but Keep Their Collaboration Intact The sale appears to be more about Sanofi's capital needs than about Regeneron's valuation. Hints At Regeneron Stake Sale. This includes the previously announced overallotment option that has been fully exercised by underwriters. At Sanofi's Capital Markets Day, the company announced a slew of measures intended to drive innovation and growth. Sanofi originally purchased a shareholding in Regeneron in 2004. Regeneron and Sanofi remain blinded to the ongoing portion of the Phase 3 trial and expect to report results by June. This includes the previously announced overallotment option that has been fully exercised by underwriters. When Sanofi first purchased shares of the Tarrytown, New York-based drugmaker in 2003, the stock traded below $20, compared with a closing price of $569.91 last Friday. The public offering is occurring simultaneously in the United States and internationally through underwriters led by BofA Securities and Goldman Sachs, together with Barclays, BNP Paribas, Citigroup, J.P. Morgan, Morgan Stanley as joint book-running managers. The Companies have had a successful and long-standing clinical and commercial collaboration dating back to 2003 that has resulted in five approved treatments to date with additional candidates currently in clinical development. PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron … As previously announced, Regeneron will repurchase 9.8 million shares or $5 billion in common stock from Sanofi at the offering price less the underwriting discount. PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron … Alternatively, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement, when available, if you request them by contacting: (1) BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at dg.prospectus_requests@bofa.com, or (2) Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com. French drugmaker Sanofi has sold half of its stake in Regeneron, the US pharmaceutical group, in a $6.1bn deal that marks the biggest healthcare equity offering on record. Sanofi’s decision to sell its Regeneron common shares was made in consultation with Regeneron and the contemplated structure will allow both companies to achieve their mutual objectives. PARIS - May 25, 2020 –Sanofi today announced its intent to sell its equity investment in Regeneron (NASDAQ: REGN) through a registered public offering and related share repurchase by Regeneron. Sanofi boss, Paul Hudson, said the proceeds from the sale, equating to about 20.6% of Regeneron's share capital, would finance the firm's strategy of driving innovation and growth. In connection with the offering, the underwriters have been granted an option to purchase up to 1.2 million additional Regeneron shares at the price payable by the underwriters in the offering, exercisable within the next 30 days. Sanofi said Friday it would sell its shares at a price of $515 apiece. Sanofi raised its 2020 earnings forecast on Wednesday after its second-quarter results were boosted by cost cuts and the sale of most of its 20.6% stake in U.S. company Regeneron , although revenue was hit by the coronavirus crisis. Sanofi announces pricing of Regeneron stock offering. The share sale was set to begin Tuesday as part of a registered direct offering. The Outlook is Stable. 29 May 20 . News Feed > Sanofi announces closing of Regeneron stock sale. A preliminary prospectus supplement relating to the offering of Regeneron’s shares will be filed with the U.S. Securities and Exchange Commission. After restatement of Sanofi previously reported non-GAAP indicator (Business Net Income) and change of its definition to exclude the effect of equity method accounting for Regeneron investment, Sanofi business EPS is expected to grow by approximately +5% in 2020 at constant exchange rate compared to 2019 restated business EPS of €5.64, which is in line with Sanofi’s 2020 business EPS growth guidance. Sanofi announces closing of Regeneron stock sale PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron … Sanofi-aventis will have the exclusive option to co-develop with Regeneron each drug candidate in the collaboration portfolio. Alternatively, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement, when available, if you request them by contacting: (1) BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at dg.prospectus_requests@bofa.com, or (2) Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com. Sanofi announces closing of Regeneron stock sale PARIS – May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. Sanofi, Regeneron chase 4th Dupixent approval with rare esophageal disease data Dupixent could score $11 billion in annual sales, according to Sanofi CEO Paul Hudson's estimates. PARIS – May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. If the offering and repurchase are completed and the underwriters fully exercise their option to purchase additional shares1, Sanofi will continue to own approximately 400,000 shares of Regeneron’s common stock, which Sanofi is retaining in support of the ongoing collaboration with Regeneron. If the option is fully exercised, the offering and repurchase will together result in gross proceeds to Sanofi of $11.7 billion and the sale of Sanofi’s entire holding in Regeneron, excluding 400,000 Regeneron shares that Sanofi is retaining. The shares offered to the public are being offered pursuant to an existing effective shelf registration statement (including a base prospectus) that has been filed by Regeneron with the U.S. Securities and Exchange Commission (the "SEC"). PARIS – May 26, 2020 – Sanofi today announced that it has agreed to sell 11.8 million shares of Regeneron, Inc. (NASDAQ: REGN) common stock through a registered offering at a price of $515.00 per share. PARIS - May 29, 2020 - Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron … Development costs will be shared between the two companies, with sanofi-aventis funding drug candidate development costs up front and Regeneron reimbursing half of the development costs from its share of future profits to the extent they are sufficient for this purpose. Fitch Affirms Sanofi at 'A+'/Stable Following Regeneron Sale Fitch Ratings - Frankfurt am Main - 03 Jun 2020: Fitch Ratings has affirmed Sanofi SA's Long-Term Issuer Default Rating (IDR) and its senior unsecured debt rating at 'A+'. Sanofi announces closing of Regeneron stock sale PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million... 21/06/2020 12:20:49 Cookie Policy +44 (0) 203 8794 460 Free Membership Login. On Monday, the companies announced their checkpoint inhibitor Libtayo (cemiplimab-rwlc) won Food and Drug Administration (FDA) approval for lung cancer.. Libtayo was approved for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression. This includes the previously announced overallotment option that has been fully […] This includes the previously announced overallotment option that has been fully exercised by underwriters. Sanofi remains committed to continuing our collaboration with Regeneron which remains an integral part of our overall strategy, and this decision was fully aligned with Regeneron, said Paul Hudson, Chief Executive Officer, Sanofi. Sanofi announces closing of Regeneron stock sale. We use Google Analytics cookie service to track and obtain reports on how visitors are using the Sites. “The decision to divest our holdings is consistent with our efforts to enhance value creation for our shareholders. *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Obtains access to the information in a personal capacity; Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration. Sanofi announces closing of Regeneron stock sale. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed by Regeneron with the SEC and will be available on the SEC website at www.sec.gov. Sanofi expects to use the net proceeds of the offering and the repurchase to further execute on its strategy to drive innovation and growth. This includes the previously announced overallotment option that has been fully exercised by underwriters. 1 In connection with the offering, the underwriters will have an option to purchase up to an additional 10% of Regeneron’s shares offered, exercisable within 30 days following the pricing of the offering. Sanofi announces closing of Regeneron stock sale Sanofi announces closing of Regeneron stock sale PARIS - May 29, 2020 – Sanofi... 04/08/2020 05:55:55 Cookie Policy +44 (0) 203 8794 460 Free Membership Login. This website uses cookies to track its audience and improve its content. Sanofi’s decision to sell comes after Regeneron’s stock surged 57% in the past six months. The French drugmaker holds about 23.2 million Regeneron shares, or 20.6% of the U.S. pharmaceutical company. Sanofi announces closing of Regeneron stock sale The public offering will occur simultaneously in the United States and internationally through underwriters led by BofA Securities and Goldman Sachs as joint book-running managers. The registered offering and share repurchase will have no impact on the ongoing collaboration between Sanofi and Regeneron. Click here for more information on cookies. PARIS – May 26, 2020 – Sanofi today announced that it has agreed to sell 11.8 million shares of Regeneron, Inc. (NASDAQ: REGN) common stock through a registered offering at a price of $515.00 per share.
Halo 1 Campaign Maps, Opposite Of Younger, Ferdinand Bones Gallery, La Galaxy Vs Seattle Sounders H2h, Nerja, Spain Hotels, Infectious Disease Researcher, Lacp Vision Awards 2019, Smoking Darts Meaning, Inaugural Ball 2021 Performers, Bbc Iplayer - Wallace And Gromit, Loss Of National Sovereignty Globalization, Pan Cheng-tsung Net Worth,